Comparative effectiveness of dapagliflozin versus non-insulin, non-SGLT2i glucose lowering medications on renal-wide endpoints in type 2 diabetes. A Real-World Italian Multicenter Study
Confronto di efficacia tra dapagliflozin ed farmaci ipoglicemizzanti (non insulina, non altri SGLT2 inibitori) su endpoints renali nel diabete tipo 2. Studio real-world multicentrico italiano.
Pubblicazioni
- Fadini GP, Del Prato S, Avogaro A, Solini A. Challenges and opportunities in real-world evidence on the renal effects of sodium-glucose cotransporter-2 inhibitors. Diabetes Obes Metab. 2022 Feb;24(2):177-186.
- Fadini GP, Longato E, Morieri ML, Del Prato S, Avogaro A, Solini A; DARWIN-Renal Study Investigators. Long-term benefits of dapagliflozin on renal outcomes of type 2 diabetes under routine care: a comparative effectiveness study on propensity score matched cohorts at low renal risk. Lancet Reg Health Eur. 2024 Feb 1;38:100847.
